Clinical Trials

24 enrolled

Lymphoid

Hodgkin Disease

NCT06066333 2026-04-15

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

12 enrolled

Endocrine

Adrenocortical Carcinoma

NCT06669572 2026-04-15

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07213934 2026-04-15

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07455032 2026-04-15

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Phase 1 Recruiting

22 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05239624 2026-04-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT05913388 2026-04-13

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

92 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT05969496 2026-04-13

NEOPAX

17 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04317534 2026-04-08

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

244 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT07301268 2026-04-08

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

36 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Gliosarcoma

NCT05812807 2026-04-07

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Phase 3 Recruiting

1,295 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT06632327 2026-04-07

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

1,100 enrolled

Lung Neoplasms

NCT06661720 2026-04-07

STRIKE

Phase 3 Recruiting

1,040 enrolled

Carcinoma, Renal Cell

NCT05286437 2026-04-06

LaPemERLA

Breast

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06745882 2026-04-02

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

318 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled

Gynecologic

Vulvar Neoplasms

NCT05524935 2026-04-01

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

37 enrolled

Dermatologic

Uveal Melanoma

NCT03449238 2026-03-30

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

776 enrolled

Tumor-Agnostic

Neoplasms

NCT07501650 2026-03-30

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Phase 1 Recruiting

6 enrolled

Head and Neck Neoplasms, Recurrence

NCT07465276 2026-03-27

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04858269 2026-03-24

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

32 enrolled

Phase EARLY_PHASE1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

30 enrolled

Carcinoma, Renal Cell

NCT06863402 2026-03-24

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05669846 2026-03-23

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

26 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06493019 2026-03-23

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

23 enrolled

Gastrointestinal

Anus Neoplasms

NCT05027633 2026-03-20

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04253964 2026-03-19

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07027124 2026-03-19

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer